Literature DB >> 11858873

Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.

Peter Amersdorfer1, Cindy Wong, Theresa Smith, Steven Chen, Sharad Deshpande, Robert Sheridan, James D Marks.   

Abstract

Understanding the antibody response in botulinum intoxication is important for vaccine design and passive prophylaxis. To investigate this activity, we have studied the immune response to BoNT/A (botulinum neurotoxin serotype A) binding domain (HC) at the molecular level using phage display. The scFv antibodies were isolated from V-gene repertoires prepared from (a) human volunteer immunized with pentavalent botulinum toxoid and (b) non-immune human peripheral blood lymphocytes and spleenocytes. A large panel of serotype specific phage expressing botulinum binding scFv could be selected from both libraries. Epitope mapping of immune scFv binders towards BoNT/A HC revealed surprisingly a limited number of scFv recognizing conformational epitopes that corresponded to two distinct groups, clusters I and II. Only scFv from cluster I exhibited neutralizing activity in the mouse hemidiaphragm assay. Anti- BoNT/A HC clones derived from a non-immune library could be conveniently grouped into clusters III-XI and appeared to share no overlapping epitopes with cluster I or II. In addition they showed no neutralization of toxin at biologically significant concentrations. We therefore suggest that a vaccine based on the pentavalent botulinum toxoid directs the humoral immune response to a limited number of immunodominant epitopes exposed on the binding domain HC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858873     DOI: 10.1016/s0264-410x(01)00482-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

3.  Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.

Authors:  Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2009-07-05       Impact factor: 5.857

4.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Authors:  R Levy; C M Forsyth; S L LaPorte; I N Geren; L A Smith; J D Marks
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

5.  Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.

Authors:  Grant E Boldt; Jack P Kennedy; Mark S Hixon; Laura A McAllister; Joseph T Barbieri; Saul Tzipori; Kim D Janda
Journal:  J Comb Chem       Date:  2006 Jul-Aug

6.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.

Authors:  Katerina Capková; Yoshiyuki Yoneda; Tobin J Dickerson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2007-10-09       Impact factor: 2.823

8.  N-Terminal labeling of filamentous phage to create cancer marker imaging agents.

Authors:  Zachary M Carrico; Michelle E Farkas; Yu Zhou; Sonny C Hsiao; James D Marks; Harshal Chokhawala; Douglas S Clark; Matthew B Francis
Journal:  ACS Nano       Date:  2012-08-06       Impact factor: 15.881

9.  Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies.

Authors:  Marvin G Warner; Jay W Grate; Abby Tyler; Richard M Ozanich; Keith D Miller; Jianlong Lou; James D Marks; Cynthia J Bruckner-Lea
Journal:  Biosens Bioelectron       Date:  2009-06-26       Impact factor: 10.618

10.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.